88.01MMarket Cap-3.81P/E (TTM)
1.230High1.230Low172Volume1.230Open1.190Pre Close211.56Turnover0.00%Turnover RatioLossP/E (Static)71.55MShares49.00052wk High2.13P/B6.77MFloat Cap0.85052wk Low--Dividend TTM5.50MShs Float49.000Historical High--Div YieldTTM0.00%Amplitude0.850Historical Low1.230Avg Price1Lot Size
Citius Oncology Stock Forum
Well since it wont be able to pick stocks, here are a few:
$AEye (LIDR.US)$ Bought at .83 to hold until Thursday before ER in case short sellers dec...
Citius Oncology Preps LYMPHIR Cancer Drug Launch While Strategic Review Unfolds
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for Lymphir by Centers for Medicare and Medicaid Services
PR Newswire· 4 mins ago
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
Tuesday, 7th January at 8:08 am
CRANFORD, N.J., Jan. 7, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ: CTXR) and its oncology-focused subsidiary, Citius Oncology (NASDAQ: CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an i...
📊⚡️📊
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives
Monday, 6th January at 7:50 am
CRANFORD, N.J., Jan. 6, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or "the Company") (NASDAQ: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ: CTXR), today announced that it has retained Jefferies LLC as its exclusive financial advisor to assist in evaluating strategic alter...
📊⚡️📊
📊⚡️📊
No comment yet